Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This neoadjuvant trial for patients with TNBC and/or gBRCA breast cancer, aims to investigate the safety and efficacy (improvement in pathological Complete Response at surgery) of concurrent platinum-based chemotherapy with olaparib an inhibitor of the PARP enzyme (PARPi).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 16 do 70 lat
- •Pisemna zgoda na udział w badaniu i gotowość do uczestniczenia przez cały okres trwania badania
- •Potwierdzony histologicznie rak piersi
- •Rak piersi ujemny w stosunku do receptorów ER i HER2 (TNBC) lub dodatni w stosunku do mutacji BRCA oraz ujemny HER2
- •Guz wielkości T1, T2, T3 lub T4 z rozszerzeniem na ścianę klatki piersiowej lub skórę albo rak zapalny
- •Powiększone węzły chłonne pachy lub węzły nad/pod obojczykiem i potwierdzony rak piersi w biopsji węzła
- •Zdolność do otrzymania chemioterapii według opinii lekarza oraz prawidłowa funkcja szpiku, wątroby i nerek
- •Rozpoczęcie leczenia w ciągu 6 tygodni od biopsji diagnostycznej
✗ Disqualifies
- •Brak guza pierwotnego bez powiększonych węzłów chłonnych
- •Rak TNBC wykazujący silne receptory androgenowe
- •Wcześniejsza chemioterapia lub leki biologiczne do leczenia raka w ciągu ostatnich 5 lat
- •Inne nowotwory w ciągu ostatnich 5 lat
Simplified criteria — AI translation
Trial details
- Minimum age
- 16 Years
- Maximum age
- 70 Years
- Last updated (source)
- November 14, 2022
- Sex
- No restrictions
Therapies / drugs in trial
Locations (30)
Cambridge University Hospitals NHS Foundation Trust & the University of Cambridge
Cambridge, United Kingdom
Queen's Hospital
Burton-on-Trent, United Kingdom
The Christie
Manchester, United Kingdom
Pinderfields General Hospital
Wakefield, United Kingdom
University Hospital Ayr
Ayr, United Kingdom
Basingstoke and North Hampshire Hospital
Basingstoke, United Kingdom
Bedford General Hospital
Bedford, United Kingdom
Royal Bournemouth Hospital
Bournemouth, United Kingdom
Bristol Haematology & Cancer Centre
Bristol, United Kingdom
West Suffolk Hospital
Bury St Edmunds, United Kingdom
Velindre Cancer Centre
Cardiff, United Kingdom
Colchester General Hospital
Colchester, United Kingdom
Russells Hall Hospital
Dudley, United Kingdom
Hinchingbrooke Hospital
Huntingdon, United Kingdom
Ipswich Hospital
Ipswich, United Kingdom
Kidderminster General Hospital
Kidderminster, United Kingdom
University Hospital Crosshouse
Kilmarnock, United Kingdom
University College London Hospital
London, United Kingdom
Royal Free Hospital
London, United Kingdom
Mount Vernon Cancer Centre
Northwood, United Kingdom
Nottingham City Hospital
Nottingham, United Kingdom
Churchill Hospital
Oxford, United Kingdom
Peterborough City Hospital
Peterborough, United Kingdom
Poole Hospital
Poole, United Kingdom
The Alexandra Hopsital
Redditch, United Kingdom
Queen's Hospital
Romford, United Kingdom
Southampton General Hospital
Southampton, United Kingdom
Singleton Hospital
Swansea, United Kingdom
Royal Hampshire County Hospital
Winchester, United Kingdom
Worcestershire Royal Hospital
Worcester, United Kingdom
Trial contact
CCTC A Cambridge Cancer Trials Centre
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.